Related Experiment Videos
Prevention of tumor metastasis formation by anti-variant CD44
1Deutsches Krebsforschungszentrum, Institut für Radiologie und Pathophysiologie, Heidelberg, Germany.
Abstract:
A splice variant of CD44 (CD44v) originally discovered on metastases of a rat pancreatic adenocarcinoma (BSp73ASML) has been shown by transfection to confer metastatic behavior to nonmetastatic tumor cells (Günthert U., M. Hofmann, W. Rudy, S. Reber, M. Zöller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. Cell. 65:13). A monoclonal antibody (mAb), 1.1ASML, to the metastasis-specific domain of the CD44v molecule retards growth of lymph node and lung metastases of the metastatic tumor line BSp73ASML, and can efficiently prevent formation of metastases by the transfected line. The antibody is only effective when given before lymph node colonization. Anti-CD44v does not downregulate the expression of CD44v, and prevention of metastatic growth by anti-CD44v is not due to activation of any kind of immune defense. We suggest that the mAb interferes with proliferation of metastasizing tumor cells in the draining lymph node, most probably by blocking a ligand interaction. The interference with metastatic spread will greatly facilitate the exploration of the function of CD44v and, in particular, may also open new strategies for the therapy of human metastases.
Insights
A monoclonal antibody targeting the CD44v variant protein effectively prevents cancer metastasis by interfering with tumor cell proliferation in lymph nodes. This discovery offers new therapeutic strategies for treating metastatic cancers.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- A specific splice variant of CD44 (CD44v) is associated with cancer metastasis.
- CD44v was initially identified on metastases of a rat pancreatic adenocarcinoma (BSp73ASML).
- Transfection studies demonstrated that CD44v confers metastatic potential to nonmetastatic tumor cells.
Purpose of the Study:
- To investigate the role of CD44v in cancer metastasis.
- To evaluate the efficacy of a monoclonal antibody (mAb) targeting CD44v in preventing metastasis.
- To elucidate the mechanism by which anti-CD44v antibodies affect metastatic spread.
Main Methods:
- Utilized a metastatic rat pancreatic adenocarcinoma cell line (BSp73ASML) and a transfected nonmetastatic cell line.
- Administered a monoclonal antibody (mAb) 1.1ASML, specific to the metastasis-specific domain of CD44v.
- Assessed the impact of mAb 1.1ASML on lymph node and lung metastasis formation and growth.
- Investigated whether anti-CD44v treatment affects CD44v expression or elicits an immune response.
Main Results:
- The mAb 1.1ASML significantly retarded the growth of existing metastases and prevented new metastasis formation in the transfected cell line.
- Antibody efficacy was dependent on administration timing, specifically before lymph node colonization.
- Anti-CD44v treatment did not alter CD44v expression levels or activate immune defenses.
- The mechanism is proposed to involve interference with ligand interactions crucial for tumor cell proliferation in lymph nodes.
Conclusions:
- The metastasis-specific CD44v molecule plays a critical role in the metastatic process.
- Monoclonal antibody targeting CD44v is a promising strategy for inhibiting cancer metastasis.
- Further research into CD44v function and anti-CD44v therapies could lead to new treatments for human metastases.